SPENT: Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Sponsor
Sun Yat-sen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04676789
Collaborator
(none)
30
1
1
40
0.8

Study Details

Study Description

Brief Summary

Aim of the trial is to evaluate the safety and efficacy of sintilimab and pegaspargase in combination with pegaspargase for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma.All eligible patients will be treated with sintilimab combined with pegaspargase administered every 3 weeks for 4 cycles followed by standard radiotherapy with or without concurrent sintilimab and pegaspargase administered every 3 weeks. After radiotherapy, patients with complete remission with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.

Condition or Disease Intervention/Treatment Phase
  • Drug: Pegaspargase
  • Drug: Anti-PD-1 monoclonal antibody
  • Radiation: Definitive intensity-modulated radiotherapy (IMRT)
Phase 2

Detailed Description

This is a multicentre, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of sintilimab and pegaspargase in combination with pegaspargase for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma.All eligible patients will be firstly treated with sintilimab combined with pegaspargase administered every 3 weeks for 4 cycles. If the patient achieves complete remission(CR), standard radiotherapy will be performed, otherwise, they will receive concurrent chemoradiotherapy(CCRT)(radiation 50 Gy and two cycles of sintilimab and pegaspargase every 3 weeks). After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
treatment with sintilimab and pegaspargase combined with intensity-modulated radiotherapy (IMRT)treatment with sintilimab and pegaspargase combined with intensity-modulated radiotherapy (IMRT)
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy As First-Line Treatment in Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention/treatment

Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.

Drug: Pegaspargase
Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
Other Names:
  • P-ASP
  • Drug: Anti-PD-1 monoclonal antibody
    Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
    Other Names:
  • sintilimab
  • Radiation: Definitive intensity-modulated radiotherapy (IMRT)
    Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
    Other Names:
  • IMRT
  • Outcome Measures

    Primary Outcome Measures

    1. progression free survival (PFS) [Baseline up to data cut-off (up to approximately 4 years)]

      Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria2016 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy, or death from any cause, whichever occurred first.

    Secondary Outcome Measures

    1. complete remission (CR) rate [At the end of Cycle 6 (each cycle is 21 days)]

      Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria and 2016 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    2. overall response rate (ORR) [At the end of Cycle 6 (each cycle is 21 days)]

      Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria and 2016 Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    3. overall survival (OS) [Baseline up to data cut-off (up to approximately 4 years)]

      Overall survival in the overall study population was defined as the time from the date of diagnosis to the date of death from any cause. Reported is the percentage of participants with event.

    4. Duration of response [Baseline up to data cut-off (up to approximately 4 years)]

      Time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with PET-CT.

    5. EBV-DNA load change [At the end of Cycle 6 (each cycle is 21 days)]

      EBV-DNA load at each cycle for comparison

    6. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [Baseline up to data cut-off (up to approximately 4 years)]

      An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • newly diagnosed ENKTL

    • age:18-80years

    • Ann Arbor stage IE,or stage IIE

    • at lease one measurable lesion

    • receive no chemotherapy or radiotherapy before

    • Eastern CooperativeOncology Group performance status of 0 to 2.

    • Adequate hematologic function (eg, white blood cell ≥ 3×10e9/l,neutrophils count ≥1.5×10e9/L, and platelet count≥ 100×10e9/L),renal function (eg, serum creatinine≤1.5 mg/dL and creatinine clearance ≥50 mL minute), and hepatic function (e.g, total bilirubin≤ 2 times the upper limit of normal and aspartate and alanine transaminase levels ≤ 3 times the upper limit of normal)

    Exclusion Criteria:
    • mismatch the inclusion criteria

    • non-nasal type disease

    • systematic central nervous system involvement

    • previous or concomitant malignancies and any coexisting medical problems that could cause poor compliance with the study protocol.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sun Yat-sen University Cancer Center Guangzhou Please Select China 510060

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    • Principal Investigator: Hua Wang, MD., Sun Yat-sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    wanghua, professor, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT04676789
    Other Study ID Numbers:
    • SYSUCC-ENKTL-002
    First Posted:
    Dec 21, 2020
    Last Update Posted:
    Dec 21, 2020
    Last Verified:
    Dec 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by wanghua, professor, Sun Yat-sen University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 21, 2020